Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta

[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company committed to developing first-in-class and bes

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

Immunome, Inc. (IMNM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Immunome is evolving into a multi-asset targeted oncology platform, anchored by varegacestat's stron

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedica

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

[url="]Immunome, Inc.[/url] (Nasdaq: IMNM), a biotechnology company committed to developing first-in

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raise

Barclays analyst Lukas Shumway initiates coverage on Immunome (NASDAQ:IMNM) with a Overweight rat

[url="]Immunome[/url], Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-c

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consens

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on d

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to

Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing f

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company

Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation o

Immunome, Inc. (NASDAQ: IMNM - Get Free Report) CFO Max Rosett sold 65,000 shares of Immunome stock

9,438 shares were sold for a transaction value of ~$204,000 on April 2, 2026. This sale represented

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology comp

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The la

Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after pos

Craig-Hallum analyst Adam Vogel maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price

Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight an

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.75) per share which missed the analyst conse

HC Wainwright & Co. analyst Andres Y. Maldonado initiates coverage on Immunome (NASDAQ:IMNM)

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and mainta

Lake Street analyst Chad Messer maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price

Evercore ISI Group analyst Cory Kasimov maintains Immunome (NASDAQ:IMNM) with a Outperform and ra

Guggenheim analyst Michael Schmidt maintains Immunome (NASDAQ:IMNM) with a Buy and raises the pri

Immunome shares trade higher on Monday after the company announced results from the global pivotal P

In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option

Immunome stock surges after positive results from Phase 3 trial for desmoid tumors, meeting all key

Truist Securities analyst Karina Rabayeva initiates coverage on Immunome (NASDAQ:IMNM) with a Buy

Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight an